Quinfamide is an antiamoebic agent primarily used for the treatment of intestinal amoebiasis caused by Entamoeba histolytica. It belongs to the quinoline derivative class and acts directly on trophozoites in the intestinal lumen, disrupting their cell membranes and metabolic activity. Quinfamide is not systemically absorbed, making it particularly effective for luminal infections without affecting extraintestinal amoebiasis.
It is typically administered as an oral tablet or suspension.
Indications include:
∙ Acute and chronic intestinal amoebiasis
∙ Amoebic cyst carriers (asymptomatic treatment)
∙ Preventive therapy in endemic regions
Impurities in quinfamide arise from chemical synthesis involving quinoline intermediates, acetylation, and amide coupling reactions, as well as from hydrolytic and oxidative degradation. As it is a gastrointestinal drug used in vulnerable populations (including children), impurity control is essential under ICH Q3A/B and relevant pharmacopeial limits.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Quinfamide is used to treat intestinal amoebiasis, particularly infections caused by Entamoeba histolytica. It is effective in eliminating trophozoites and cysts from the intestinal lumen.
It likely acts by disrupting cell membranes and interfering with nucleic acid synthesis in protozoal cells, although the exact mechanism is not fully elucidated.
Yes, it is commonly prescribed to children and adults in areas where amoebiasis is endemic. Pediatric formulations are available.
Quinfamide is moderately stable, but susceptible to hydrolysis and oxidation. It should be stored in airtight containers, protected from light, moisture, and heat.
